Gynaecomastia only one side — known clinically as unilateral gynaecomastia — is a relatively common presentation in which glandular breast tissue enlarges in just one male breast. Although the condition often affects both sides, each breast can respond independently to hormonal signals, meaning asymmetric or entirely one-sided growth is entirely possible. Understanding why this occurs, what causes it, and when to seek medical advice is essential, as not all unilateral breast swelling in men is benign. This article explains the causes, red flag symptoms, NHS diagnosis pathways, treatment options, and how to distinguish gynaecomastia from other breast conditions, including male breast cancer.

Why Gynaecomastia Can Affect Only One Side

Gynaecomastia affects only one side because each breast responds independently to hormonal signals; localised differences in oestrogen receptor density or aromatase activity can cause glandular proliferation in one breast while the other remains unaffected.

Have any more questions about this? Message our pharmaceutical team to get more info →

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting from an imbalance between oestrogen and androgen activity within breast tissue. While the condition often affects both breasts simultaneously, it is entirely possible — and relatively common — for it to present on only one side, a presentation known as unilateral gynaecomastia.

The asymmetry occurs because each breast responds independently to hormonal signals. Even when circulating hormone levels are the same throughout the body, local tissue sensitivity to oestrogen can differ between the left and right breast. One side may have a higher density of oestrogen receptors or greater aromatase enzyme activity, which converts androgens into oestrogens at the tissue level. This localised variation means that one breast may develop glandular proliferation while the other remains unaffected.

It is also worth noting that bilateral gynaecomastia can sometimes appear unilateral in its early stages, with the second side developing enlargement weeks or months later. This sequential onset can cause initial concern, but it does not necessarily indicate a more serious underlying condition.

Not all unilateral breast swelling in men represents true gynaecomastia. Pseudogynaecomastia (fatty tissue accumulation without glandular proliferation) and, importantly, male breast cancer must also be considered — these are discussed in detail in the final section below. Any new or unexplained unilateral breast swelling in a male should always be assessed by a healthcare professional to rule out other causes. Further information on causes and assessment is available from NICE CKS: Gynaecomastia and the NHS gynaecomastia patient page.

Common Causes of One-Sided Breast Tissue Enlargement in Men

Common causes include puberty, ageing, medications such as spironolactone and finasteride, anabolic steroids, and underlying conditions including hypogonadism, hyperthyroidism, and liver cirrhosis; in a significant proportion of cases no cause is identified.

A wide range of factors can trigger unilateral gynaecomastia, and identifying the underlying cause is an important part of clinical assessment. The most frequently encountered causes include:

• Hormonal fluctuations: Puberty is the most common trigger in younger males, with a substantial proportion of adolescent boys experiencing some degree of gynaecomastia during this period. Hormonal changes during ageing (particularly after the age of 50) are also a significant factor.

• Medications: Several commonly prescribed drugs are associated with gynaecomastia. These include spironolactone, cimetidine, bicalutamide, finasteride, ketoconazole, digoxin, certain antipsychotics, some antidepressants (SSRIs and tricyclics), and certain antiretrovirals. Prescribers and patients should consult the BNF and individual Summary of Product Characteristics (SmPC) for specific agents; the MHRA has issued Drug Safety Updates for particular medicines where this association is clinically significant. If you suspect a medicine is causing a side effect, you can report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

• Recreational substances: Anabolic steroids used in bodybuilding and alcohol have been linked to breast tissue changes in men. Cannabis has also been cited in some reports, though the evidence is largely observational and remains mixed.

• Underlying medical conditions: Hypogonadism, hyperthyroidism, liver cirrhosis, chronic kidney disease, and adrenal or testicular tumours can all disrupt the oestrogen–androgen balance.

• Idiopathic causes: In a significant proportion of cases, no identifiable cause is found despite thorough investigation.

When gynaecomastia affects only one side, clinicians must also consider the possibility of a unilateral benign cyst, lipoma, or — importantly — male breast cancer, which, although rare, accounts for fewer than 400 diagnoses per year in the UK (Cancer Research UK). A thorough history and examination remain essential first steps in differentiating these possibilities.

When to See a GP About Unilateral Gynaecomastia

See a GP promptly if you notice a new lump, nipple discharge, skin changes, a hard or fixed mass, or nipple retraction — these features require urgent assessment to exclude male breast cancer.

Many men feel embarrassed or uncertain about seeking help for breast changes, but prompt assessment is important, particularly when the enlargement is one-sided. You should contact your GP if you notice any of the following:

• A new lump or swelling on one side of the chest that was not previously present

• Pain or tenderness in the breast tissue, especially if it is worsening

• Nipple discharge, particularly if it is bloodstained or occurs without squeezing

• Skin changes over the breast, such as dimpling, puckering, tethering, redness, or ulceration

• A hard, irregular, or fixed lump that does not move freely under the skin

• Nipple retraction or inversion

• Persistent eczema, crusting, or scaling of the nipple–areola complex (which may suggest Paget's disease of the nipple — see NHS: Paget's disease of the nipple)

• Swollen lymph nodes in the armpit on the same side

True gynaecomastia typically presents as a rubbery or firm, disc-like mound of tissue directly beneath the nipple–areola complex, and is usually mildly tender. In contrast, male breast cancer more commonly presents as a hard, painless, eccentric lump that may be fixed to surrounding tissue, though pain does not exclude malignancy.

In line with NICE NG12 (Suspected cancer: recognition and referral), GPs should refer men aged 50 and over with a unilateral, firm subareolar mass — with or without nipple retraction or discharge — urgently via the two-week wait pathway for suspected cancer. At any age, urgent referral is warranted when clinical features are suspicious, including a hard, irregular, or fixed mass; skin tethering or ulceration; suspicious axillary lymphadenopathy; or features suggestive of inflammatory breast disease or Paget's disease of the nipple. Even if the eventual diagnosis is benign, early assessment provides reassurance and ensures that any serious pathology is not missed. There is no need to wait and see if the swelling resolves on its own when these red flag features are present.

How Unilateral Gynaecomastia Is Diagnosed on the NHS

NHS diagnosis begins with clinical history and examination, followed by blood tests, testicular ultrasound if indicated, and breast imaging using a triple-assessment approach; NICE NG12 supports urgent two-week wait referral when cancer is suspected.

Diagnosis of unilateral gynaecomastia on the NHS begins with a thorough clinical assessment by a GP or specialist. The consultation will typically include a detailed medical and medication history, a review of any recreational drug or supplement use, and a physical examination of both breasts, the testes, and the lymph nodes.

If the GP suspects an underlying hormonal cause or wishes to exclude malignancy, they may arrange a range of investigations, which can include:

• Blood tests: Serum testosterone, luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, prolactin, beta-human chorionic gonadotrophin (beta-hCG — to detect hCG-secreting tumours), thyroid function tests, liver function tests, and renal function tests

• Testicular ultrasound: Considered when testicular examination is abnormal or when tumour markers or hormone levels are raised, to exclude a testicular tumour that may be secreting hormones driving breast tissue growth

• Breast imaging: UK breast units use a triple-assessment approach (clinical examination, imaging, and where necessary biopsy). Ultrasound is frequently the first-line imaging modality; mammography may be added, particularly in older men or when malignancy is suspected. The choice of modality is guided by local breast clinic protocols in line with Royal College of Radiologists (RCR iRefer) and Association of Breast Surgery (ABS) guidance

• Biopsy: If imaging reveals a suspicious lesion, a core needle biopsy may be performed to obtain a tissue diagnosis

Referral to a breast clinic or endocrinology service may be arranged depending on findings. NICE NG12 supports urgent two-week wait referral for men with breast symptoms that could indicate cancer (see criteria above). In straightforward cases where a benign hormonal cause is identified and red flag features are absent, the GP may manage the condition in primary care with appropriate monitoring and reassurance, in line with NICE CKS: Gynaecomastia.

Treatment Options Available in the UK

Treatment depends on the underlying cause and symptom duration; options include addressing causative factors, off-label medical therapy such as tamoxifen in the early active phase, or surgery for longstanding cases, subject to NHS ICB commissioning criteria.

The management of unilateral gynaecomastia depends on the underlying cause, the duration of symptoms, the degree of discomfort, and the impact on the individual's quality of life. In many cases, particularly in adolescents, the condition resolves spontaneously within one to two years without any specific treatment.

Addressing the underlying cause is always the first step. If a causative medication is identified, the prescribing clinician may consider switching to an alternative where clinically appropriate — this decision should always be made in consultation with the prescriber and must not be done without medical advice. Similarly, treating an underlying condition such as hyperthyroidism or hypogonadism may lead to regression of breast tissue over time.

Medical therapy is occasionally used in the early, active phase of gynaecomastia — typically within the first six to twelve months of onset — when the tissue is still responsive to hormonal intervention and most likely to benefit. Options that have been used include:

• Tamoxifen (an oestrogen receptor antagonist) — currently has the strongest evidence base and is used off-label in the UK

• Raloxifene — another selective oestrogen receptor modulator (SERM) with some evidence of benefit, also used off-label

• Aromatase inhibitors (such as anastrozole) — evidence is limited and these are not routinely recommended in UK practice; use should be under specialist guidance only

These medications are not licensed specifically for gynaecomastia in the UK. Their use should be guided by a specialist, with appropriate informed consent regarding off-label prescribing.

Surgical treatment is available for cases that are longstanding, symptomatic, or causing significant psychological distress. Surgical options include subcutaneous mastectomy or liposuction-assisted techniques. Access to surgery on the NHS is subject to local Integrated Care Board (ICB) commissioning policies and exceptionality processes; it is generally considered only when conservative measures have failed and there is a demonstrable impact on mental health or daily functioning. Men who do not meet NHS criteria may wish to explore private surgical options, which are available across the UK. Further guidance on management is available from NICE CKS: Gynaecomastia.

Distinguishing Gynaecomastia from Other Breast Conditions

True gynaecomastia presents as a firm, disc-like mound beneath the nipple, whereas male breast cancer typically appears as a hard, irregular, fixed, or eccentric lump; UK breast clinics use triple assessment to differentiate these conditions reliably.

Not all breast swelling in men represents true gynaecomastia, and accurate differentiation is clinically important. Several other conditions can mimic the appearance of unilateral gynaecomastia and must be considered during assessment.

Pseudogynaecomastia (also called lipomastia) refers to the accumulation of fatty tissue in the chest without any true glandular proliferation. It is commonly seen in men who are overweight or obese and typically affects both sides, though asymmetry can occur. On examination, the tissue feels soft and fatty rather than firm and disc-like, and it is not centred beneath the nipple.

Male breast cancer, though rare, is the most important condition to exclude. It accounts for fewer than 400 diagnoses per year in the UK (Cancer Research UK). Key distinguishing features include:

• A hard, irregular, or fixed lump, often eccentric to the nipple

• Nipple retraction or inversion

• Bloodstained nipple discharge

• Skin tethering or ulceration

• Painless presentation (though pain does not exclude malignancy)

• Persistent eczema, crusting, or scaling of the nipple–areola complex, which may indicate Paget's disease of the nipple (see NHS: Paget's disease of the nipple)

Other benign conditions to consider include epidermal cysts, lipomas, haematomas following trauma, and — rarely — metastatic deposits from other primary tumours.

Clinical examination alone cannot always reliably distinguish between these conditions. UK symptomatic breast clinics use a triple-assessment approach — combining clinical examination, imaging, and biopsy where indicated — as the standard diagnostic pathway, in line with RCR iRefer and ABS guidance. Men should be reassured that the majority of unilateral breast changes are benign, but that seeking timely medical advice is always the right course of action. Early assessment not only provides peace of mind but ensures that any serious pathology is identified and managed promptly.

Frequently Asked Questions